Patent EP-0133530-A3 (EP)
Title: 1,6-naphthyridinone derivatives, process for their preparation, and medicaments containing them
IPC: C07D471/04
Filed: 1984-07-30
Abstract: 1. Claims (for the Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE) Naphthyridinone derivatives of the general formula I  see diagramm : EP0133530,P12,F4  wherein R**1 is a phenyl radical, which in 2- and/or 3-position may be substituted by halogen atoms, such as fluorine, chlorine or bromine, by nitro, trifluoromethyl, methoxy, difluoromethoxy, or cyano groups or lower alkylamino groups, preferably dimethylamino groups or diethylamino groups, or represents an unsubstituted pyridyl or thienyl radical, R**2 is hydrogen, an alkyl or alkylaminoalkyl group of the general formula II  see diagramm : EP0133530,P13,F1  wherein R**5 and R**6 may be the same or different and represent a straight-chained or branched alkyl group with 1-4 C-atoms or represent together an alkylene group with 4-6 C-atoms, n represents the figure 2 or 3, R**3 is an amino group or a methyl or ethyl group and R**4 represents hydrogen or a straight-chained, branched or cyclic alkyl or alkoxyalkyl radical containing up to 6 carbon atoms, as well as optionally the pharmacologically safe salts thereof. 1. Claim (for the Contracting State AT) Process for the preparation of 1,6-naphthyridinone-derivatives of the general formula I  see diagramm : EP0133530,P14,F4  wherein R**1 is a phenyl radical, which in 2- and/or 3-position may be substituted by halogen atoms, such as fluorine, chlorine or bromine, by nitro, trifluoromethyl, methoxy, difluoromethoxy, or cyano groups or lower alkylamino groups, preferably dimethylamino groups or diethylamino groups, or represents an unsubstituted pyridyl or thienyl radical, R**2 is hydrogen, an alkyl or alkylaminoalkyl group of the general formula II  see diagramm : EP0133530,P15,F1  wherein R**5 and R**6 may be the same or different and represent a straight-chained or branched alkyl group with 1-4 C-atoms or represent together an alkylene group with 4-6 C-atoms, n represents the figure 2 or 3, R**3 is an amino group or a methyl or ethyl group and R**4 represents hydrogen or a straight-chained, branched or cyclic alkyl or alkoxyalkyl radical containing up to 6 carbon atoms, as well as optionally the pharmacologically safe salts thereof, characterized in that either a) 2,4-dihydroxypyridine is reacted in the presence of ammonia with a compound of the general formula III  see diagramm : EP0133530,P15,F2 wherein R**1 , R**3 and R**4 have the aforementioned meaning, and the compounds so obtained of the general formula IV  see diagramm : EP0133530,P15,F3  wherein R**1 , R**3 and R**4 have the aforementioned meaning, are reacted, if desired, in a manner known per se with a compound of the general formula V X-R**2 , wherein R**2 represents an alkyl or alkoxyalkyl group or an alkylamino alkyl group of the general formula II and X represents a halogen atom or b) a 1,4-dihydropyridine of the general formula  see diagramm : EP0133530,P15,F4  wherein R**1 , R**3 and R**4 have the aforementioned meaning and R**7 represents an alkyl radical containing 1-4 carbon atoms, is reacted with s-triazine in the presence of a base and the compound obtained of the general formula IV is, if desired, subsequently alkylated or amino-alkylated with a compound of the general formula V or c) a 1,4-dihydropyridine of the general formula VI is reacted with a dialkylformamide-dialkyl acetal of the general formula VII  see diagramm : EP0133530,P15,F5  wherein R**8 may be the same or different and represent a methyl or ethyl group and the radicals R**9 represent alkyl groups containing up to 4 carbon atoms or represent together an alkylene group containing up to 3 carbon atoms and the compound obtained of the general formula VIII see diagramm : EP0133530,P15,F6  wherein R**1 , R**3 , R**4 and R**8 have to aforementioned meaning, is converted into a compound of the general formula IV by means of ammonia, alkylating or amino-alkylating it, if desired, with a compound of the general formula V and converting the compounds obtained of the general formula I into their pharmacologically acceptable salts, optionally by reaction with organic or inorganic acids.